Literature DB >> 17442923

Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response.

Joke M M den Haan1, Georg Kraal, Michael J Bevan.   

Abstract

TLR ligands are potent activators of dendritic cells and therefore function as adjuvants for the induction of immune responses. We analyzed the capacity of TLR ligands to enhance CD8+ T cell responses toward soluble protein Ag. Immunization with OVA together with LPS or poly(I:C) elicited weak CD8+ T cell responses in wild-type C57BL/6 mice. Surprisingly, these responses were greatly increased in mice lacking CD4+ T cells indicating the induction of regulatory CD4+ T cells. In vivo, neutralization of IL-10 completely restored CD8+ T cell responses in wild-type mice and OVA-specific IL-10 producing CD4+ T cells were detected after immunization with OVA plus LPS. Our study shows that TLR ligands not only activate the immune system but simultaneously induce Ag specific, IL-10-producing regulatory Tr1 cells that strongly suppress CD8+ T cell responses. In this way, excessive activation of the immune system may be prevented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442923      PMCID: PMC2776046          DOI: 10.4049/jimmunol.178.9.5429

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Regulatory T cells and mechanisms of immune system control.

Authors:  Anne O'Garra; Paulo Vieira
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

Review 2.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.

Authors:  Karl S Lang; Mike Recher; Tobias Junt; Alexander A Navarini; Nicola L Harris; Stefan Freigang; Bernhard Odermatt; Curdin Conrad; Lars M Ittner; Stefan Bauer; Sanjiv A Luther; Satoshi Uematsu; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  Nat Med       Date:  2005-01-16       Impact factor: 53.440

4.  Cutting edge: TLR ligands are not sufficient to break cross-tolerance to self-antigens.

Authors:  Emma E Hamilton-Williams; Andreas Lang; Dirk Benke; Gayle M Davey; Karl-Heinz Wiesmüller; Christian Kurts
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

Review 5.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

6.  Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta.

Authors:  Vanessa Durand; Simon Yc Wong; David F Tough; Agnes Le Bon
Journal:  Immunol Cell Biol       Date:  2004-12       Impact factor: 5.126

7.  Differential antigen processing by dendritic cell subsets in vivo.

Authors:  Diana Dudziak; Alice O Kamphorst; Gordon F Heidkamp; Veit R Buchholz; Christine Trumpfheller; Sayuri Yamazaki; Cheolho Cheong; Kang Liu; Han-Woong Lee; Chae Gyu Park; Ralph M Steinman; Michel C Nussenzweig
Journal:  Science       Date:  2007-01-05       Impact factor: 47.728

8.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

9.  Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells.

Authors:  Matthew A Williams; Michael J Bevan
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

10.  Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells.

Authors:  Megan K Levings; Silvia Gregori; Eleonora Tresoldi; Sabrina Cazzaniga; Chiara Bonini; Maria Grazia Roncarolo
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

View more
  31 in total

1.  Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo.

Authors:  Rajakumar Mandraju; Sean Murray; James Forman; Chandrashekhar Pasare
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

Review 2.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

3.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

Review 4.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

Review 5.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

6.  β2-adrenergic stimulation of dendritic cells favors IL-10 secretion by CD4+ T cells.

Authors:  Julie Hervé; Karine Haurogné; Elodie Bacou; Sylvie Pogu; Marie Allard; Grégoire Mignot; Jean-Marie Bach; Blandine Lieubeau
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

7.  Nitric oxide modulates lipopolysaccharide-induced endothelial platelet endothelial cell adhesion molecule expression via interleukin-10.

Authors:  C B Hebeda; S A Teixeira; E K Tamura; M N Muscará; S B V de Mello; R P Markus; S H P Farsky
Journal:  Clin Exp Immunol       Date:  2011-05-12       Impact factor: 4.330

Review 8.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

9.  Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes.

Authors:  Paul Ashwood; Amanda Enstrom; Paula Krakowiak; Irva Hertz-Picciotto; Robin L Hansen; Lisa A Croen; Sally Ozonoff; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

10.  Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF.

Authors:  Jeremy P McAleer; Robert J Rossi; Anthony T Vella
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.